When kids with ADHD need medicines to help with symptoms like hyperactivity, inattention, or impulsivity, doctors usually suggest stimulants first. But some children don’t respond well to these drugs ...

Extended-release guanfacine was safe and effective for short-term treatment of hyperactivity, impulsiveness and distractibility in children with autism spectrum disorder, according to study findings ...

A new study assessed the safety, tolerability, and effectiveness of extended-release guanfacine in children 6-17 years of age who have chronic tic disorders including Tourette's disorder. Researchers ...

"The approval of INTUNIV marks a significant advance in the treatment of ADHD in children and adolescents in Europe. Previously, physicians had only one licensed non-stimulant option for these ...

September 3, 2009 — The US Food and Drug Administration has approved guanfacine extended-release tablets (Intuniv; Shire plc) for the once-daily treatment of attention-deficit hyperactivity disorder ...

San Francisco, CA – May 18, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a ...

FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents First once-daily nonstimulant to be ...

The first selective alpha-2A adrenergic receptor agonist licensed for the treatment of ADHD in the EU Shire (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission granted Marketing ...